Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s stock price traded down 32.7% on Friday . The stock traded as low as $1.01 and last traded at $1.01. 2,700 shares traded hands during mid-day trading, an increase of 50% from the average session volume of 1,800 shares. The stock had previously closed at $1.50.
Silence Therapeutics Price Performance
The firm’s 50 day moving average price is $2.63 and its two-hundred day moving average price is $5.15.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Recommended Stories
- Five stocks we like better than Silence Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Investing In Automotive Stocks
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
